Ken earned his undergraduate and M.S. (Cell Biology) degrees from Western Michigan University, Kalamazoo, Michigan in 1987 and 1989, respectively. In 1993, he obtained his Ph.D. in Pharmacology at the University of Michigan followed by postdoctoral training in the Department of Pathology (University of Michigan). Over the next 23 years, Ken held a series of positions in the pharmaceutical industry with stops at Pfizer and GlaxoSmithKline, where he was Head of Translational Pharmacology for the ImmunoInflammation Center of Excellence. In 2009, Ken joined Janssen Pharmaceuticals, where he established the ImmunoPharmacology Group (Immunology TA) which focused on in vivo modeling and translational sciences. Upon being named a Director in 2010, Ken formed the Early Proof-of-Concept group which sought to establish non-traditional, external collaborations/alliances to rapidly progress early-stage assets. After leaving Janssen In 2019, Ken joined Princeton University as an Executive-in-Residence. The following year, he joined Beyond Celiac, a non-profit organization focused on developing treatments for celiac disease, where he served as the Chief Scientific Investment Officer for the organization. Ken is an author on over 60 scientific publications and completed his Executive MBA at St. Joseph’s University (Philadelphia, PA). He is also active in the venture capital and biotech start-up communities in both Pennsylvania and Michigan. Ken currently resides in Berwyn, Pennsylvania with his wife and two daughters.